CatherineAnnShuMD

Hematologic Oncology, Thoracic Cancer

Physician

Overview of Dr. Shu

Dr. Catherine Shu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 8 years. She is one of 369 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 20 publications and over 500 citings.

Office
161 Fort Washington Avenue
New York, NY 10032
Book by Phone+1(951) 795-4273
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology
Princeton UniversityBSE

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2010 - 2025
NJ State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Start of enrollment: 2016 Jun 07
Completed
Phase 2
SGI-110 Plus Durvalumab/Tremelimumab in SCLC Start of enrollment: 2017 Dec 15
Completed
Phase 1
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Start of enrollment: 2022 Dec 01
Withdrawn
Phase 2
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation Start of enrollment: 2022 Dec 15
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.
Rohan Maniar, Stephanie M Gallitano, Sameera Husain, Golnaz Moazami, Michael J Weiss, Catherine A Shu> ;Journal of the National Comprehensive Cancer Network. 2023 Feb 9
8 citations
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, Catherine A Shu, Kristen A Marrone, Xiuning Le, Collin M Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde ...> ;Journal of Thoracic Oncology. 2023 May 1
2 citations
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Lanyi Nora Chen, Alexander Z Wei, Catherine A Shu> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
6 citations
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
Rohan Maniar, Peter H Wang, Robert S Washburn, Radomir Kratchmarov, Shana M Coley, Anjali Saqi, Samuel S Pan, Jianhua Hu, Catherine A Shu, Naiyer A Rizvi, Brian S Heni...> ;Cancer Immunology Research. 2023 Feb 3
6 citations
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
Anjali Saqi, Kevin O Leslie, Andre L Moreira, Sylvie Lantuejoul, Catherine Ann Shu, Naiyer A Rizvi, Joshua R Sonett, Kosei Tajima, Shawn W Sun, Barbara J Gitlitz, Thom...> ;JTO Clinical and Research Reports. 2022 May 1
13 citations
Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
Anup Kumar Biswas, Seoyoung Han, Yifan Tai, Wanchao Ma, Courtney Coker, S Aidan Quinn, Ahmad Rushdi Shakri, Timothy James Zhong, Hanna Scholze, Galina G Lagos, Angelik...> ;Cancer Discovery. 2022 Apr 1
ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Gener...
Carleigh R. Canterbury, Helen Fernandes, John P. Crapanzano, Vundavalli V. Murty, Mahesh M. Mansukhani, Catherine A. Shu, Matthias Szabolcs, Anjali Saqi> ;JTO Clinical and Research Reports. 2021 Sep 25
8 citations
What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
Catherine A. Shu, Tina Cascone> ;Journal of Clinical Oncology. 2021 Aug 2
239 citations
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee, Joshua K. ...> ;Journal of Clinical Oncology. 2021 Aug 2
2 citations
Hepatoid Adenocarcinoma of the Lung Responsive to Frontline Combination Chemotherapy With Immunotherapy: Case Report.
Galina G. Lagos, Jarett L. Feldman, Anjali Saqi, Catherine A. Shu> ;JTO Clinical and Research Reports. 2021 Feb 1
11 citations
Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States.
Michael S. May, Connor J. Kinslow, Christopher M. Adams, Anjali Saqi, Catherine A. Shu, Kunal R. Chaudhary, Tony J. C. Wang, Simon K. Cheng> ;Translational Lung Cancer Research. 2021 Jan 1
7 citations
Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease.
David Andrew Bender, Samuel P. Heilbroner, Tony J. C. Wang, Catherine A. Shu, Brigham Hyde, Catherine S. Spina, Simon K. Cheng> ;Journal for Immunotherapy of Cancer. 2020 Dec 1
12 citations
Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management.
Simon Sung, Jonas J. Heymann, John P. Crapanzano, Andre L. Moreira, Catherine A. Shu, William A. Bulman, Anjali Saqi> ;Journal of the American Society of Cytopathology. 2020 Sep 1
6 citations
Characteristics and outcomes of lung cancer in solid organ transplant recipients.
Lanyi Nora Chen, John H Spivack, Thu Cao, Anjali Saqi, Luke Benvenuto, William A. Bulman, Matthen Mathew, Mark B. Stoopler, Selim M. Arcasoy, Bryan P. Stanifer, Naiyer...> ;Lung Cancer. 2020 Jun 20
8 citations
Synchronous Pulmonary Adenocarcinomas
Carlos A. Pagan, Catherine A. Shu, John P. Crapanzano, Galina G Lagos, Mark B. Stoopler, Naiyer A. Rizvi, Jonas J. Heymann, Joshua R. Sonett, Helen Fernandes, Anjali Saqi> ;American Journal of Clinical Pathology. 2020 Jun 8
317 citations
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Catherine A. Shu, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Claud Grigg, Aliyah Pabani, Robert Garofano, Mark B. Stoopler, Simon K. Cheng, Abby White, Michael L...> ;The Lancet. Oncology. 2020 Jun 1
4 citations
Pulmonary small cell carcinoma: Review, common and uncommon differentials, genomics and management.
Simon Sung, Maryam Shirazi, Catherine A. Shu, John P. Crapanzano, Anjali Saqi> ;Diagnostic Cytopathology. 2020 Apr 29
31 citations
Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
Connor J. Kinslow, Michael S. May, Anjali Saqi, Catherine A. Shu, Kunal R. Chaudhary, Tony J. C. Wang, Simon K. Cheng> ;Clinical Lung Cancer. 2020 Mar 1
18 citations
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
Ezra Y. Rosen, Alison M. Schram, Robert J. Young, Mark Schreyer, Jaclyn F. Hechtman, Catherine A. Shu, Nora Ku, David M. Hyman, Alexander Drilon> ;JCO Precision Oncology. 2019 May 16
31 citations
Effects of β-adrenergic antagonists on chemoradiation therapy for locally advanced non-small cell lung cancer
Kunal R. Chaudhary, Sherry X. Yan, Samuel P. Heilbroner, Joshua R. Sonett, Mark B. Stoopler, Catherine A. Shu, Balazs Halmos, Tony J. C. Wang, Tom K. Hei, Simon K. Cheng> ;Journal of Clinical Medicine. 2019 Apr 26
204 citations
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Joshua K. Sabari, Giulia Costanza Leonardi, Catherine A. Shu, Renato Umeton, Joseph Montecalvo, Ai Ni, Ruqin Chen, Jules L. Dienstag, Chebli Mrad, Isabella Bergagnini,...> ;Annals of Oncology. 2018 Oct 1
84 citations
Combining chemotherapy with PD-1 blockade in NSCLC.
Matthen Mathew, Thomas Enzler, Catherine A. Shu, Naiyer A. Rizvi> ;Pharmacology & Therapeutics. 2018 Jan 31
29 citations
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Matthen Mathew, Rachael A. Safyan, Catherine A. Shu> ;Annals of Translational Medicine. 2017 Sep 1
148 citations
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Jonas J. Heymann, William A. Bulman, David Swinarski, Carlos A. Pagan, John P. Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B. Stoopler, Joshua R. Sonett, Adr...> ;Cancer Cytopathology. 2017 Dec 1
1 citations
Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply.
Catherine A. Shu, Malcolm C. Pike, Noah D. Kauff> ;JAMA Oncology. 2017 Mar 1
Join now to see all

Press Mentions

Lung Cancer Screening: Do Updated Criteria Address Racial Disparities?January 18th, 2022
Dr. Catherine Shu Discusses a Study with Important Implications in the Treatment of Lung CancerJanuary 17th, 2022
The CDC Launches a “Coronavirus Self-Checker” Bot Called Clara for People in the United StatesMarch 23rd, 2020
Join now to see all

Hospital Affiliations

New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York